PRODUCT INFORMATION

Target	PD-L1
Synonyms	B7-H; B7H1; PDL1; CD274; hPD-L1; PDCD1L1; PDCD1LG1
Description	Recombinant human PD-L1(128-238) Protein with C-terminal human Fc tag
Delivery	In Stock
Uniprot ID	Q9NZQ7
Expression Host	HEK293
Tag	C-Human Fc tag
Molecular Characterization	PD-L1(Val128-Arg238) hFc(Glu99-Ala330)
Molecular Weight	The protein has a predicted molecular mass of 38.8 kDa after removal of the signal peptide. The apparent molecular mass of PD-L1(128-238)-hFc is approximately 35-70 kDa due to glycosylation.
Purity	The purity of the protein is greater than 95% as determined by SDS-PAGE and Coomassie blue staining.
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Storage&Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Sterility	Products are supplied non-sterile. For cell culture applications, dilute in appropriate medium and sterile-filter (0.22 μm) prior to use.
Background	This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]
Usage	Research use only
Conjugate	Unconjugated



Figure 1. Human PD-L1(128-238) Protein, hFc Tag on SDS-PAGE under reducing condition.